Selected research
Industry Research
Cell Therapy CDMO Services Industry Research Report 2026
Market perspective
The global Cell Therapy CDMO Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cell Therapy CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cell Therapy CDMO Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cell Therapy CDMO Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cell Therapy CDMO Services include Thermo Fisher Scientific, Wuxi AppTec, Lonza, KBI Biopharma, RoslinCT, Cell and Gene Therapy Catapult, Cell Therapies, Minaris Regenerative Medicine and MEDINET, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cell Therapy CDMO Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cell Therapy CDMO Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cell Therapy CDMO Services Market by Company
Thermo Fisher Scientific
Wuxi AppTec
Lonza
KBI Biopharma
RoslinCT
Cell and Gene Therapy Catapult
Cell Therapies
Minaris Regenerative Medicine
MEDINET
Catalent Biologics
Oxford BioMedica
GenScript
Cell-Easy
SK pharmteco
Charles River Laboratories
AGC Biologics
FUJIFILM Cellular Dynamics
Cell Therapy CDMO Services Segment by Type
Preclinical Stage
Clinical Commercialization Stage
Cell Therapy CDMO Services Segment by Application
Pharmaceutical Company
Research Institute
Cell Therapy CDMO Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cell Therapy CDMO Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Preclinical Stage
- Clinical Commercialization Stage
Applications
- Pharmaceutical Company
- Research Institute
Companies covered
- Thermo Fisher Scientific
- Wuxi AppTec
- Lonza
- KBI Biopharma
- RoslinCT
- Cell and Gene Therapy Catapult
- Cell Therapies
- Minaris Regenerative Medicine
- MEDINET
- Catalent Biologics
- Oxford BioMedica
- GenScript
- Cell-Easy
- SK pharmteco
- Charles River Laboratories
- AGC Biologics
- FUJIFILM Cellular Dynamics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cell Therapy CDMO Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Preclinical Stage
- 2.2.3 Clinical Commercialization Stage
- 2.3 Cell Therapy CDMO Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Company
- 2.3.3 Research Institute
- 2.4 Assumptions and Limitations
3 Cell Therapy CDMO Services Breakdown Data by Type
- 3.1 Global Cell Therapy CDMO Services Historic Market Size by Type (2021-2026)
- 3.2 Global Cell Therapy CDMO Services Forecasted Market Size by Type (2027-2032)
4 Cell Therapy CDMO Services Breakdown Data by Application
- 4.1 Global Cell Therapy CDMO Services Historic Market Size by Application (2021-2026)
- 4.2 Global Cell Therapy CDMO Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cell Therapy CDMO Services Market Perspective (2021-2032)
- 5.2 Global Cell Therapy CDMO Services Growth Trends by Region
- 5.2.1 Global Cell Therapy CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cell Therapy CDMO Services Historic Market Size by Region (2021-2026)
- 5.2.3 Cell Therapy CDMO Services Forecasted Market Size by Region (2027-2032)
- 5.3 Cell Therapy CDMO Services Market Dynamics
- 5.3.1 Cell Therapy CDMO Services Industry Trends
- 5.3.2 Cell Therapy CDMO Services Market Drivers
- 5.3.3 Cell Therapy CDMO Services Market Challenges
- 5.3.4 Cell Therapy CDMO Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cell Therapy CDMO Services Players by Revenue
- 6.1.1 Global Top Cell Therapy CDMO Services Players by Revenue (2021-2026)
- 6.1.2 Global Cell Therapy CDMO Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Cell Therapy CDMO Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cell Therapy CDMO Services Head Office and Area Served
- 6.4 Global Cell Therapy CDMO Services Players, Product Type & Application
- 6.5 Global Cell Therapy CDMO Services Manufacturers Established Date
- 6.6 Global Cell Therapy CDMO Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cell Therapy CDMO Services Market Size (2021-2032)
- 7.2 North America Cell Therapy CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cell Therapy CDMO Services Market Size by Country (2021-2026)
- 7.4 North America Cell Therapy CDMO Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cell Therapy CDMO Services Market Size (2021-2032)
- 8.2 Europe Cell Therapy CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cell Therapy CDMO Services Market Size by Country (2021-2026)
- 8.4 Europe Cell Therapy CDMO Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cell Therapy CDMO Services Market Size (2021-2032)
- 9.2 Asia-Pacific Cell Therapy CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cell Therapy CDMO Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cell Therapy CDMO Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cell Therapy CDMO Services Market Size (2021-2032)
- 10.2 South America Cell Therapy CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cell Therapy CDMO Services Market Size by Country (2021-2026)
- 10.4 South America Cell Therapy CDMO Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cell Therapy CDMO Services Market Size (2021-2032)
- 11.2 Middle East & Africa Cell Therapy CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cell Therapy CDMO Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cell Therapy CDMO Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific Cell Therapy CDMO Services Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Wuxi AppTec
- 12.2.1 Wuxi AppTec Company Information
- 12.2.2 Wuxi AppTec Business Overview
- 12.2.3 Wuxi AppTec Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.2.4 Wuxi AppTec Cell Therapy CDMO Services Product Portfolio
- 12.2.5 Wuxi AppTec Recent Developments
- 12.3 Lonza
- 12.3.1 Lonza Company Information
- 12.3.2 Lonza Business Overview
- 12.3.3 Lonza Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.3.4 Lonza Cell Therapy CDMO Services Product Portfolio
- 12.3.5 Lonza Recent Developments
- 12.4 KBI Biopharma
- 12.4.1 KBI Biopharma Company Information
- 12.4.2 KBI Biopharma Business Overview
- 12.4.3 KBI Biopharma Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.4.4 KBI Biopharma Cell Therapy CDMO Services Product Portfolio
- 12.4.5 KBI Biopharma Recent Developments
- 12.5 RoslinCT
- 12.5.1 RoslinCT Company Information
- 12.5.2 RoslinCT Business Overview
- 12.5.3 RoslinCT Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.5.4 RoslinCT Cell Therapy CDMO Services Product Portfolio
- 12.5.5 RoslinCT Recent Developments
- 12.6 Cell and Gene Therapy Catapult
- 12.6.1 Cell and Gene Therapy Catapult Company Information
- 12.6.2 Cell and Gene Therapy Catapult Business Overview
- 12.6.3 Cell and Gene Therapy Catapult Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.6.4 Cell and Gene Therapy Catapult Cell Therapy CDMO Services Product Portfolio
- 12.6.5 Cell and Gene Therapy Catapult Recent Developments
- 12.7 Cell Therapies
- 12.7.1 Cell Therapies Company Information
- 12.7.2 Cell Therapies Business Overview
- 12.7.3 Cell Therapies Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.7.4 Cell Therapies Cell Therapy CDMO Services Product Portfolio
- 12.7.5 Cell Therapies Recent Developments
- 12.8 Minaris Regenerative Medicine
- 12.8.1 Minaris Regenerative Medicine Company Information
- 12.8.2 Minaris Regenerative Medicine Business Overview
- 12.8.3 Minaris Regenerative Medicine Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.8.4 Minaris Regenerative Medicine Cell Therapy CDMO Services Product Portfolio
- 12.8.5 Minaris Regenerative Medicine Recent Developments
- 12.9 MEDINET
- 12.9.1 MEDINET Company Information
- 12.9.2 MEDINET Business Overview
- 12.9.3 MEDINET Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.9.4 MEDINET Cell Therapy CDMO Services Product Portfolio
- 12.9.5 MEDINET Recent Developments
- 12.10 Catalent Biologics
- 12.10.1 Catalent Biologics Company Information
- 12.10.2 Catalent Biologics Business Overview
- 12.10.3 Catalent Biologics Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.10.4 Catalent Biologics Cell Therapy CDMO Services Product Portfolio
- 12.10.5 Catalent Biologics Recent Developments
- 12.11 Oxford BioMedica
- 12.11.1 Oxford BioMedica Company Information
- 12.11.2 Oxford BioMedica Business Overview
- 12.11.3 Oxford BioMedica Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.11.4 Oxford BioMedica Cell Therapy CDMO Services Product Portfolio
- 12.11.5 Oxford BioMedica Recent Developments
- 12.12 GenScript
- 12.12.1 GenScript Company Information
- 12.12.2 GenScript Business Overview
- 12.12.3 GenScript Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.12.4 GenScript Cell Therapy CDMO Services Product Portfolio
- 12.12.5 GenScript Recent Developments
- 12.13 Cell-Easy
- 12.13.1 Cell-Easy Company Information
- 12.13.2 Cell-Easy Business Overview
- 12.13.3 Cell-Easy Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.13.4 Cell-Easy Cell Therapy CDMO Services Product Portfolio
- 12.13.5 Cell-Easy Recent Developments
- 12.14 SK pharmteco
- 12.14.1 SK pharmteco Company Information
- 12.14.2 SK pharmteco Business Overview
- 12.14.3 SK pharmteco Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.14.4 SK pharmteco Cell Therapy CDMO Services Product Portfolio
- 12.14.5 SK pharmteco Recent Developments
- 12.15 Charles River Laboratories
- 12.15.1 Charles River Laboratories Company Information
- 12.15.2 Charles River Laboratories Business Overview
- 12.15.3 Charles River Laboratories Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.15.4 Charles River Laboratories Cell Therapy CDMO Services Product Portfolio
- 12.15.5 Charles River Laboratories Recent Developments
- 12.16 AGC Biologics
- 12.16.1 AGC Biologics Company Information
- 12.16.2 AGC Biologics Business Overview
- 12.16.3 AGC Biologics Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.16.4 AGC Biologics Cell Therapy CDMO Services Product Portfolio
- 12.16.5 AGC Biologics Recent Developments
- 12.17 FUJIFILM Cellular Dynamics
- 12.17.1 FUJIFILM Cellular Dynamics Company Information
- 12.17.2 FUJIFILM Cellular Dynamics Business Overview
- 12.17.3 FUJIFILM Cellular Dynamics Revenue in Cell Therapy CDMO Services Business (2021-2026)
- 12.17.4 FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Product Portfolio
- 12.17.5 FUJIFILM Cellular Dynamics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst